← ANALYST RATINGS · TIPRANKS
Fulgent Genetics (FLGT): analyst forecast and price target
Analyst consensus
Hold0 Buy1 Hold0 Sell
Ratings of 1 analysts in the last 3 months12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $19.00, the highest $19.00, the lowest $19.00. The average is −4.1% from the last price of $19.81.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $21.00 → $20.00−4.8% | Hold | +1.0% | Reiterated | 15.10.26on TipRanks 00:06 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $21.50 → $21.00−2.3% | Hold | +6.0% | Reiterated | 15.10.26on TipRanks 00:06 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $21.50 → $21.00−2.3% | Hold | +6.0% | Reiterated | 15.10.26on TipRanks 00:06 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $21.00 → $20.00−4.8% | Hold | +1.0% | Reiterated | 15.10.26on TipRanks 00:06 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $21.50 → $21.00−2.3% | Hold | +6.0% | Reiterated | 15.10.26on TipRanks 00:06 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $22.00 → $22.50+2.3% | Hold | +13.6% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $15.00 → $19.00+26.7% | Hold | −4.1% | Reiterated | 04.08.26on TipRanks 07:45 | +3.5%next day +0.1% · 5 days +2.5% | ↗ |
| Lu Li★★★★★★★★★★#5185 · hits 80% · avg +11.8% | UBS | $35.00 → $22.00−37.1% | Buy | +11.1% | Reiterated | 02.03.26on TipRanks 09:15 | −7.4%next day −2.0% · 5 days +6.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Fulgent Genetics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $19.00 at a price of $22.02 (−13.7%); now: $19.00 at $19.81 (−4.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.65 (from $-0.65 to $-0.65). Last quarter: $-0.58.
Sales
Next quarter’s sales estimate — $86M (from $86M to $86M). Last quarter: $85M.
Best top-analyst consensus in the sector · Healthcare
About Fulgent Genetics
- CEO: Ming Hsieh
- Employees: 1,315
- 4978 Santa Anita Avenue, El Monte, CA, 91731, US
- www.fulgentgenetics.com
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
Data from the stock’s TipRanks forecast page, read 21 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗